Neuronetics Inc reports results for the quarter ended June 30 - Earnings Summary
Neuronetics Inc reports results for the quarter ended June 30 - Earnings Summary
Neuronetics Inc STIM.OQ reported a quarterly adjusted loss of 4 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -15 cents. The mean expectation of four analysts for the quarter was for a loss of 12 cents per share. Wall Street expected results to range from -13 cents to -11 cents per share.
Revenue rose 9.1% to $41.57 million from a year ago; analysts expected $40.18 million.
Neuronetics Inc's reported EPS for the quarter was a loss of 5 cents.
The company reported a quarterly loss of $3.44 million.
Neuronetics Inc shares had risen by 66.9% this quarter and gained 57.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 0.7% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"
Wall Street's median 12-month price target for Neuronetics Inc is $4.00, about 45.8% above its last closing price of $2.17
This summary was machine generated from LSEG data August 11 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.12 | -0.04 | Beat |
Mar. 31 2026 | -0.17 | -0.15 | Beat |
Dec. 31 2025 | -0.11 | -0.10 | Beat |
Sep. 30 2025 | -0.13 | -0.13 | Met |
Recent news on Neuronetics
See all newsNeuronetics Inc reports results for the quarter ended June 30 - Earnings Summary
Neuronetics Q2 revenue beats estimates on Greenbrook clinic strength
Neuronetics Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Neuronetics Appoints Nir Naor Chief Financial Officer Announces Additional Management Changes